Patents by Inventor Thomas STEROVSKY

Thomas STEROVSKY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant human IgM-antibody effective against cancer cells
    Patent number: 10590204
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: March 17, 2020
    Assignee: KATINGER GMBH
    Inventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
  • RECOMBINANT HUMAN IgM-ANTIBODY EFFECTIVE AGAINST CANCER CELLS
    Publication number: 20180237538
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Application
    Filed: February 8, 2018
    Publication date: August 23, 2018
    Inventors: Hermann KATINGER, Renate KUNERT, Thomas STEROVSKY, Thomas HEMETSBERGER
  • Recombinant human IgM-antibody effective against cancer cells
    Patent number: 9920130
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: March 20, 2018
    Assignee: KATINGER GMBH
    Inventors: Hermann Katinger, Renate Kunert, Thomas Sterovsky, Thomas Hemetsberger
  • RECOMBINANT HUMAN IgM-ANTIBODY EFFECTIVE AGAINST CANCER CELLS
    Publication number: 20150322161
    Abstract: A recombinant human monoclonal pentameric IgM antibody comprising the capability of oligospecific binding to purified ganglioside epitopes GD3, GM3, GD2 and GM1 and the capability of specific binding to malignant cancer cells selected from the group consisting of melanoma cells, small cell lung cancer cells, glioblastoma cells, and estrogen receptor-negative metastatic breast cancer cells; a cell line producing the IgM antibody; and the use of the IgM antibody as a diagnostic tool and/or as a therapeutic agent.
    Type: Application
    Filed: November 26, 2013
    Publication date: November 12, 2015
    Applicant: Katinger GmbH
    Inventors: Hermann KATINGER, Renate KUNERT, Thomas STEROVSKY, Thomas HEMETSBERGER